ATE418999T1 - Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung - Google Patents

Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung

Info

Publication number
ATE418999T1
ATE418999T1 AT99949656T AT99949656T ATE418999T1 AT E418999 T1 ATE418999 T1 AT E418999T1 AT 99949656 T AT99949656 T AT 99949656T AT 99949656 T AT99949656 T AT 99949656T AT E418999 T1 ATE418999 T1 AT E418999T1
Authority
AT
Austria
Prior art keywords
myeloma
multiple myeloma
integrin
receptor binding
bone resorption
Prior art date
Application number
AT99949656T
Other languages
German (de)
English (en)
Inventor
Gregory Mundy
Toshiyuki Yoneda
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE418999T1 publication Critical patent/ATE418999T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
AT99949656T 1998-09-14 1999-09-13 Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung ATE418999T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
ATE418999T1 true ATE418999T1 (de) 2009-01-15

Family

ID=22278506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99949656T ATE418999T1 (de) 1998-09-14 1999-09-13 Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung

Country Status (28)

Country Link
US (1) US7211252B2 (https=)
EP (2) EP2065050A1 (https=)
JP (3) JP2002524529A (https=)
KR (1) KR100628818B1 (https=)
CN (1) CN1236815C (https=)
AT (1) ATE418999T1 (https=)
AU (1) AU757873B2 (https=)
BR (1) BR9913705A (https=)
CA (1) CA2343579C (https=)
CY (1) CY1109413T1 (https=)
CZ (1) CZ302997B6 (https=)
DE (1) DE69940206D1 (https=)
DK (1) DK1113810T3 (https=)
EA (1) EA004270B1 (https=)
EE (1) EE05558B1 (https=)
ES (1) ES2319831T3 (https=)
HU (1) HU229038B1 (https=)
IL (2) IL141877A0 (https=)
IS (1) IS2631B (https=)
NO (2) NO327855B1 (https=)
NZ (1) NZ511062A (https=)
PL (1) PL203114B1 (https=)
PT (1) PT1113810E (https=)
SI (1) SI1113810T1 (https=)
SK (1) SK287601B6 (https=)
TR (1) TR200100734T2 (https=)
WO (1) WO2000015247A2 (https=)
ZA (1) ZA200102032B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2263485T3 (es) * 1999-09-14 2006-12-16 Biogen Idec Ma Inc. Terapia para insuficiencia renal cronica utilizando uno o mas angtagonistas de integrinas.
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2002356180A1 (en) 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
EA009873B1 (ru) * 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP3461499A1 (en) * 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CA2711256C (en) * 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101238061B1 (ko) 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
SMT202000306T1 (it) * 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN103619874A (zh) * 2011-06-30 2014-03-05 株式会社免疫生物研究所 可溶性整联蛋白α4突变体
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
CN103215223B (zh) * 2013-03-18 2014-10-29 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN103838980A (zh) * 2014-03-27 2014-06-04 山东大学 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2017205560A1 (en) * 2016-05-27 2017-11-30 Albert Einstein College Of Medicine, Inc. Methods for treating cancer by targeting vcam1 and maea
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
DK0626861T4 (da) 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
JPH07506566A (ja) 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
DK0670735T3 (da) 1992-11-13 1997-07-28 Univ Washington Perifisering af hæmotopoietiske stamceller.
SG52262A1 (en) 1993-01-08 1998-09-28 Tanabe Seiyaku Co Peptide inhibitors of cell adhesion
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US5885786A (en) * 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
DK0923941T3 (da) * 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
HUP0102255A3 (en) * 1998-05-28 2001-12-28 Biogen Idec Ma Inc Cambridge Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
WO2000015247A8 (en) 2009-12-23
EE200100146A (et) 2002-06-17
IL141877A0 (en) 2002-03-10
EP1113810B1 (en) 2008-12-31
CN1236815C (zh) 2006-01-18
TR200100734T2 (tr) 2001-07-23
NZ511062A (en) 2003-04-29
PL347128A1 (en) 2002-03-25
SI1113810T1 (sl) 2009-04-30
SK287601B6 (sk) 2011-03-04
CZ2001916A3 (cs) 2001-08-15
PT1113810E (pt) 2009-03-10
EP1113810A2 (en) 2001-07-11
CN1321091A (zh) 2001-11-07
PL203114B1 (pl) 2009-08-31
CY1109413T1 (el) 2014-08-13
NO327855B1 (no) 2009-10-05
JP2010235620A (ja) 2010-10-21
CA2343579C (en) 2012-05-29
AU6248699A (en) 2000-04-03
EE05558B1 (et) 2012-08-15
ZA200102032B (en) 2002-11-07
WO2000015247A2 (en) 2000-03-23
HUP0103630A3 (en) 2004-03-01
US7211252B2 (en) 2007-05-01
NO20011244L (no) 2001-05-14
JP5378303B2 (ja) 2013-12-25
ES2319831T3 (es) 2009-05-12
JP2002524529A (ja) 2002-08-06
KR100628818B1 (ko) 2006-09-27
EA004270B1 (ru) 2004-02-26
DE69940206D1 (de) 2009-02-12
BR9913705A (pt) 2001-06-05
IS5856A (is) 2001-02-23
US20020022028A1 (en) 2002-02-21
JP2013241441A (ja) 2013-12-05
CA2343579A1 (en) 2000-03-23
HUP0103630A2 (hu) 2002-01-28
NO20011244D0 (no) 2001-03-12
WO2000015247A3 (en) 2000-05-25
KR20010085793A (ko) 2001-09-07
AU757873B2 (en) 2003-03-06
HK1038313A1 (en) 2002-03-15
IS2631B (is) 2010-06-15
NO20011283D0 (no) 2001-03-14
EA200100362A1 (ru) 2001-12-24
IL197686A0 (en) 2011-07-31
DK1113810T3 (da) 2009-04-06
HU229038B1 (hu) 2013-07-29
EP2065050A1 (en) 2009-06-03
CZ302997B6 (cs) 2012-02-15
SK6052001A3 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
ATE418999T1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
DE69939022D1 (de) Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge
ATE250424T1 (de) Zusammensetzungen und verfahren zur anregung des wachstums von neuriten
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
DE60018247D1 (de) System und Methode zur Verwendung mit bildgebenden Verfahren zur Erleichterung der Planung von chirurgischen Eingriffen
DE69806970D1 (de) Verfahren zur behandlung von hartgeweben
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
EP1109548A4 (en) Compositions and methods for treating and preventing bone diseases using tocotrienols
DE69810416D1 (de) Verfahren und Vorrichtung zur Verbesserung der Verpflanzung von Sämlingen
DE69931946D1 (de) Zusammensetzungen und verfahren zur zubereitung von dispersionen und verfahren zur verwendung der dispersionen
DE69914365D1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
EP1499190A4 (en) METHODS OF TREATING LIVER DISEASES AND LIVER LESIONS USING GROWTH HORMONE AND FOXM1B PROTEIN
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
EP0909172A4 (en) METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE WITH ENANTIOMERIC ENRICHED (R, s) -GLYCOPYRROLATE
DE69930725D1 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat
DE69732703D1 (de) Verfahren und zusammensetzung zur antiparasitären behandlung der umgebung von tieren
DE69932342D1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
DE59701111D1 (de) Verfahren zur biologisch-thermischen behandlung von abfällen
DE69839371D1 (de) Verfahren und zusammensetzung zur behandlung von substraten mit verbesserter benetzbarkeit
ATE446099T1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60037349D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1113810

Country of ref document: EP